New pill for scarred lungs shows promise in early trial
NCT ID NCT05938920
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental oral drug called INS018_055 in 71 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. The main goal was to see if the drug is safe and tolerable over 12 weeks compared to a placebo. Researchers also measured lung function changes. The trial has been completed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Chest Hospital
Hefei, Anhui, 230031, China
-
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, 100050, China
-
General Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, 300052, China
-
Hainan General Hospital
Haikou, Hainan, 570311, China
-
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, 330006, China
-
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, 510515, China
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210008, China
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100730, China
-
Peking University Shougang Hospital
Beijing, Beijing Municipality, 100041, China
-
Qilu Hospital of Shandong University
Jinan, Shandong, 250013, China
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 201800, China
-
Shanxi Bethune Hospital
Taiyuan, Shanxi, 030032, China
-
The First Affiliated Hospital - Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310006, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
-
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510080, China
-
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230601, China
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China
-
The Shengjing Hospital of China medical university
Shenyang, Liaoning, 110004, China
-
The West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
-
Xiangya Hospital of Central South University
Changsha, Hunan, 410008, China
-
Zhongshan hospital Fudan University
Shanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new daily pill slow lung scarring in IPF?
- Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
- Can a new drug slow lung scarring in IPF?
- Blood tests could unlock early clues for three major lung diseases
- AI could uncover hidden lung disease in routine chest X-Rays
- Inhaled drug could offer new hope for lung scarring disease